epacadostat (INCB024360) / Incyte  >>  Phase 2
Welcome,         Profile    Billing    Logout  

13 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
epacadostat (INCB024360) / Incyte
2016-004289-25: A Phase 1/2 Study of Azacitidine in Combination With Pembrolizumab and Epacadostat Advanced Solid Tumors including Lung and Colorectal Cancer

Ongoing
2
160
Europe
Epacadostat, azacitidine., Pembrolizumab, INCB024360, MK-3475, Tablet, Powder for injection, Powder for solution for infusion, Vidaza, KEYTRUDA
Incyte Corporation, Incyte Corporation
Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non–Small Cell Lung Cancer and Stage IV Microsatellite Stable Colorectal Cancer, Subjects With Advanced Solid Tumors and Previously Treated Non–Small Cell Lung Cancer and Colorectal Cancer, Diseases [C] - Cancer [C04]
 
 
NRG-GY016, NCT03602586: Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Checkmark Data from P2 trial in combination with Keytruda in clear cell ovarian carcinoma at IGCS 2022
Oct 2022 - Oct 2022: Data from P2 trial in combination with Keytruda in clear cell ovarian carcinoma at IGCS 2022
Active, not recruiting
2
14
US
Epacadostat, INCB 024360, INCB024360, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475
National Cancer Institute (NCI), NRG Oncology
Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma
02/21
09/24
2020-002244-23: An Open-Label, Randomized, Phase 2, Study of Various Therapies for Participants With Muscle-Invasive bladder cancer who are not eligible for Cisplatin or Refuse Cisplatin Therapy and are having bladder removal (Optimus) Studio generale in aperto, randomizzato, di fase 2 per valutare varie terapie per partecipanti con carcinoma muscolo-invasivo della vescica che sono non idonei al cisplatino o rifiutano la terapia con cisplatino e si sottopongono rimozione della vescica (Optimus)

Not yet recruiting
2
45
Europe
Epacadostat, Retifanlimab, [INCB024360], [INCMGA00012], Tablet, Solution for infusion
INCYTE CORPORATION, Incyte Corporation
Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy Carcinoma uroteliale muscolo-invasivo della vescica non idoneo al cisplatino o che rifiuta la terapia con cisplatino e si sottopone a cistectomia radicale, Muscle-Invasive Bladder cancer Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and having bladder removal Carcinoma muscolo-invasivo della vescica non idoneo al cisplatino o che rifiuta la terapia con cisplatino e con rimozione della vescica, Diseases [C] - Cancer [C04]
 
 
NCT03006302: Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

Active, not recruiting
2
41
US
Epacadostat, INCB024360, Pembrolizumab, MK-3475, KEYTRUDA, CRS-207, Cyclophosphamide, CY, CYTOXAN, GVAX Pancreas Vaccine, GVAX, Panc 10.05 pcDNA-1/GM-Neo, Panc 6.03 pcDNA-1/GM-Neo
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC, National Cancer Institute (NCI), Incyte Corporation
Metastatic Pancreatic Adenocarcinoma
08/23
08/24
NCT03414229: A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Active, not recruiting
2
30
US
Epacadostat, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Incyte Corporation, Merck Sharp & Dohme LLC, M.D. Anderson Cancer Center
Sarcoma
01/25
01/25
NCT03532295: Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Hourglass Jan 2019 - Jan 2019 : P2 trial in recurrent gliomas
Active, not recruiting
2
51
US
Epacadostat, Bevacizumab, Avastin, Radiation therapy, Peripheral blood draw, Retifanlimab, INCMGA00012
Washington University School of Medicine, Incyte Corporation
Glioma, Glioblastoma
07/24
04/26
Optimus, NCT04586244: An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Terminated
2
30
Europe, US
retifanlimab, epacadostat, INCAGN02385, INCAGN02390
Incyte Corporation
Urothelial Carcinoma
01/24
01/24
POD1UM-204, NCT04463771 / 2020-000496-20: Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Recruiting
2
300
Europe, US, RoW
retifanlimab, INCMGA00012, epacadostat, pemigatinib, INCAGN02385, INCAGN02390
Incyte Corporation, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Endometrial Cancer
04/25
05/26
DeCidE1, NCT02785250: Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Checkmark Top-line data from DeCidE1 trial in combination with DPX-Survivac
Feb 2020 - Feb 2020: Top-line data from DeCidE1 trial in combination with DPX-Survivac
Checkmark Top-line data from trial in combination with DPX-Survivac at ASCO 2018
Jun 2018 - Jun 2018: Top-line data from trial in combination with DPX-Survivac at ASCO 2018
Active, not recruiting
1b/2
85
Canada, US
DPX-Survivac, Cyclophosphamide, Epacadostat (INCB024360)
ImmunoVaccine Technologies, Inc. (IMV Inc.), Incyte Corporation
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer
10/20
05/25
2017-001743-12: A Phase 1/2, Open-Label, Dose-Rising , Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Cancers (ECHO-208)

Not yet recruiting
1/2
141
Europe
epacadostat, Nivolumab, ipilimumab, Lirilumab, INCB024360, BMS-936558, BMS-734016, BMS-986105, Tablet, Concentrate for solution for infusion, Solution for injection/infusion, OPDIVO, Yervoy
Incyte Corporation, Incyte Corporation
Phase 1 (Dose Escalation): Advanced or metastatic solid tumors. Phase 2 (Dose Expansion): Advanced or metastatic non–small cell lung cancer (NSCLC), unresectable or metastatic melanoma (MEL) and recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)., Phase 1 Advanced or metastatic solid tumors. Phase 2 Advanced or metastatic non–small cell lung cancer, unresectable or metastatic melanoma and recurrent or metastatic head and neck cancer., Diseases [C] - Cancer [C04]
 
 
2016-002423-29: A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Nivolumab in Select Advanced Cancers

Not yet recruiting
1/2
291
Europe
Epacadostat, Nivolumab, INCB024360, BMS-936558, Tablet, Solution for infusion, Opdivo
incyte Corporation, Incyte Corporation
Selected advanced cancers, including metastatic and/or unresectable solid tumors including NSCLC, melanoma,adenocarcinoma of the colon or rectum , recurrent squamous cell carcinoma of the head and neck, ovarian cancer, recurrent B cell NHL (including DLBCL) or HL, or glioblastoma., Selected advanced cancers including lung , melanoma, colon or rectum cancer, head and neck , ovarian , B cell non-Hodgkin's lymphoma or Hodgkin's lymphoma, or glioblastoma, Diseases [C] - Cancer [C04]
 
 
QuEST1, NCT03493945: Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat

Active, not recruiting
1/2
53
US
M7824, N-803, MVA-BN-Brachyury, FPV-Brachyury, Epacadostat
National Cancer Institute (NCI)
Metastatic Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor
12/24
12/24
NCT03516708: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

Hourglass Jan 2019 - Jan 2019 : P1/2 trial in advanced rectal cancer
Recruiting
1/2
39
US
Epacadostat, INCB024360, Short-course radiation, CAPOX chemotherapy
Washington University School of Medicine, Incyte Corporation, National Cancer Institute (NCI)
Rectal Cancer
07/27
08/30

Download Options